IPO Year: 2024
Exchange: NASDAQ
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a global biotechnology company that specializes in the formulation, development, and manufacturing of ingestible gel technology, announces today that its sport-focused brand Sportsgel has been named an official sponsor of the Professional Pickleball Tour and League of Australia and New Zealand, PPA Tour Australia ("PPAA"), and Major League Pickleball Australia ("MLPA"). Boasting the highest level and prize money of the sport in Oceania, PPAA and MLPA feature Pro teams, and high-profile owners including former World No.1 golfer Adam Scott, NBA Star Patty Mills, five-time Olympian Nat Cook,
NEW YORK, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a global biotechnology company that specializes in the formulation, development, and manufacturing of ingestible gel technology, announces the launch of its SportsGel brand. "SportsGel has been established to eliminate the common trade-off between performance versus taste, mouthfeel and convenience," said Nathan Givoni, Co-Founder and CEO of Gelteq. "Utilizing Gelteq's unique delivery system, SportsGel challenges the traditional sports nutrition supplement paradigm, with an improved sports performance solution tailored to the core attributes needed for each sport." The Company has also se
NEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a global biotechnology company that specializes in the formulation, development, and manufacturing of ingestible gel technology, announced today the appointment of Matthew Jones as Head of Sports Performance. He will oversee the growth, outreach, and customer strategy of Gelteq's sports vertical. "The sports industry is one of a number of key areas that Gelteq's unique formulation can pose a significant improvement to nutrient delivery over traditional methods," said Nathan Givoni, Co-Founder and CEO of Gelteq. "Matthew's pedigree aligns perfectly for this position with his global experie
NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a global biotechnology company that specializes in the formulation, development, and manufacturing of ingestible gel technology, announced today the appointment of Dr. Paul Wynne as its Chief Scientific Officer ("CSO"). Gelteq co-founder and CEO Nathan Givoni stated, "We believe Dr. Wynne's distinguished record and expertise in formulation science and drug delivery systems will be instrumental in driving the next phase of Gelteq's product pipeline. Recognized for his collaborative approach and ability to coordinate high-performing teams that drive scientific excellence, Dr. Wynne's ped
NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a clinical and biotechnology company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, sports, and other products, announces today that the U.S. Food and Drug Administration ("FDA") has approved its suitability petition for a new animal drug under development. The new animal drug leverages Gelteq's ingestible gel platform designed for nutrient and drug delivery. A suitability petition is a request by a drug sponsor to submit an abbreviated new animal drug application ("ANADA") for a proposed innovative new a
NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products, announces that its Co-Founders, CEO Mr. Nathan Givoni and Executive Chairman Mr. Simon Szewach, will be participating in the Benchmark Company 13th Annual Discovery Investor Conference being held on Wednesday, December 11, 2024, at the New York Athletic Club in New York City. Mr. Givoni and Mr. Szewach will be hosting one-on-one meetings with analysts and investors throughout the day. To schedu
NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products, announces its largest U.S. customer, Healthy Extracts (OTCQB:HYEX), has increased its initial purchase order of Gelteq collagen and Mynus sugar blocker gels by 50%, citing high demand and popularity of the products. Healthy Extracts' platform acquires, develops, patents, markets, and distributes plant-based nutraceuticals that target select high-growth categories within the multibillion-dollar n
NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products, announces today that in November, 400,000 units of its gel solution are entering into production. These units will fulfill orders made for clients in the U.S and Australia. Delivery is expected in January 2025 for sales across the two countries as well as in the UAE and in Asia. The production run includes Gelteq nutraceutical products in the areas of sports, anti-aging, and weight loss. Gelteq Co-Foun
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products, announced today that it has expanded its operations in the United States with the appointment of Adam Bendell as President of U.S. Operations. Gelteq Co-Founder and CEO Nathan Givoni stated, "The appointment of a dedicated U.S.-based President is a critical step in the execution of our growth strategy as we look to scale our operations in the U.S. market. Adam brings not only a wealth of exper
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited ("Gelteq" or the "Company"), a global biotechnology company that specializes in the formulation, development, and manufacturing of ingestible gel technology, announced today the closing of its initial public offering of 1,300,000 ordinary shares at a public offering price of US$4.00 per share. The ordinary shares commenced trading on the Nasdaq Global Market on October 29, 2024 under the symbol "GELS." The gross proceeds from the offering, before deducting underwriting fees and other offering expenses payable by the Company, were US$5.2 million. The Company intends to use the net proceeds from the offering for various purposes, in
NEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a global biotechnology company that specializes in the formulation, development, and manufacturing of ingestible gel technology, announced today the appointment of Matthew Jones as Head of Sports Performance. He will oversee the growth, outreach, and customer strategy of Gelteq's sports vertical. "The sports industry is one of a number of key areas that Gelteq's unique formulation can pose a significant improvement to nutrient delivery over traditional methods," said Nathan Givoni, Co-Founder and CEO of Gelteq. "Matthew's pedigree aligns perfectly for this position with his global experie
NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a global biotechnology company that specializes in the formulation, development, and manufacturing of ingestible gel technology, announced today the appointment of Dr. Paul Wynne as its Chief Scientific Officer ("CSO"). Gelteq co-founder and CEO Nathan Givoni stated, "We believe Dr. Wynne's distinguished record and expertise in formulation science and drug delivery systems will be instrumental in driving the next phase of Gelteq's product pipeline. Recognized for his collaborative approach and ability to coordinate high-performing teams that drive scientific excellence, Dr. Wynne's ped
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products, announced today that it has expanded its operations in the United States with the appointment of Adam Bendell as President of U.S. Operations. Gelteq Co-Founder and CEO Nathan Givoni stated, "The appointment of a dedicated U.S.-based President is a critical step in the execution of our growth strategy as we look to scale our operations in the U.S. market. Adam brings not only a wealth of exper
6-K - Gelteq Ltd (0001920092) (Filer)
20-F - Gelteq Ltd (0001920092) (Filer)
NT 20-F - Gelteq Ltd (0001920092) (Filer)
6-K - Gelteq Ltd (0001920092) (Filer)
NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products, announces its largest U.S. customer, Healthy Extracts (OTCQB:HYEX), has increased its initial purchase order of Gelteq collagen and Mynus sugar blocker gels by 50%, citing high demand and popularity of the products. Healthy Extracts' platform acquires, develops, patents, markets, and distributes plant-based nutraceuticals that target select high-growth categories within the multibillion-dollar n